|
Pharmacopeia has searched its libraries and found some promising compounds. The biotech drug discovery firm has moved from sifting through and identifying small molecule compounds, to actually taking a handful into clinical trials. Its candidates include possible therapies for hypertension and renal diseases, a non-steroidal treatment for muscle wasting, a chemokin receptor antagonist that might be useful in treating inflammatory and autoimmune diseases, and a treatment for psoriasis. It has built up a pipeline with a mix of its own discoveries and other programs it has licensed from larger companies. Pharmacopeia was acquired by drug discovery firm Ligand Pharmaceuticals in late 2008.
|
| | | Contact Information | |
Address: |
3000 Eastpark Blvd
Cranbury, NJ 08512
| | Phone: | 609-452-3600 | | Fax: | 609-452-3672 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman and Interim CEO:
Joseph A. Mollica
| | • |
SVP Business Development:
Simon M. Tomlinson
| | • |
EVP Corporate Development:
Eric J. Liebler
|
|
|
